MINI, ENRICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.218
EU - Europa 17.907
AS - Asia 13.615
SA - Sud America 2.257
OC - Oceania 301
AF - Africa 276
Continente sconosciuto - Info sul continente non disponibili 6
AN - Antartide 1
Totale 59.581
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 24.960
RU - Federazione Russa 6.979
SG - Singapore 3.855
PL - Polonia 3.854
CN - Cina 3.591
HK - Hong Kong 2.271
BR - Brasile 1.857
IE - Irlanda 1.847
KR - Corea 1.706
IT - Italia 1.644
SE - Svezia 1.092
VN - Vietnam 775
DE - Germania 693
IN - India 504
UA - Ucraina 454
FI - Finlandia 406
GB - Regno Unito 332
AU - Australia 291
JO - Giordania 244
FR - Francia 175
AR - Argentina 168
ID - Indonesia 139
CA - Canada 127
TR - Turchia 108
JP - Giappone 95
CH - Svizzera 85
EC - Ecuador 81
ES - Italia 79
MX - Messico 78
ZA - Sudafrica 68
BD - Bangladesh 64
CI - Costa d'Avorio 62
NL - Olanda 62
IQ - Iraq 57
AT - Austria 54
BE - Belgio 49
CO - Colombia 40
MA - Marocco 37
VE - Venezuela 29
BJ - Benin 26
CL - Cile 22
PE - Perù 22
PY - Paraguay 22
PK - Pakistan 20
EG - Egitto 18
SA - Arabia Saudita 18
UZ - Uzbekistan 18
AE - Emirati Arabi Uniti 17
LT - Lituania 17
SC - Seychelles 15
TH - Thailandia 15
CZ - Repubblica Ceca 14
UY - Uruguay 13
NP - Nepal 12
IL - Israele 11
IR - Iran 11
AZ - Azerbaigian 10
DO - Repubblica Dominicana 10
NZ - Nuova Zelanda 10
TW - Taiwan 10
AL - Albania 9
DZ - Algeria 9
JM - Giamaica 9
KZ - Kazakistan 9
TN - Tunisia 9
KE - Kenya 8
LB - Libano 8
GR - Grecia 7
MY - Malesia 7
OM - Oman 7
PH - Filippine 7
DK - Danimarca 6
HN - Honduras 6
RS - Serbia 6
TT - Trinidad e Tobago 6
CR - Costa Rica 5
ET - Etiopia 5
PA - Panama 5
PT - Portogallo 5
BG - Bulgaria 4
EU - Europa 4
LV - Lettonia 4
MK - Macedonia 4
NO - Norvegia 4
SK - Slovacchia (Repubblica Slovacca) 4
AM - Armenia 3
BB - Barbados 3
BO - Bolivia 3
BY - Bielorussia 3
CY - Cipro 3
GE - Georgia 3
MD - Moldavia 3
MU - Mauritius 3
NG - Nigeria 3
PS - Palestinian Territory 3
RO - Romania 3
BT - Bhutan 2
BW - Botswana 2
GT - Guatemala 2
HU - Ungheria 2
Totale 59.541
Salva come PNG Salva come JPEG
Città #
Santa Clara 5.978
Warsaw 3.826
Singapore 2.638
Fairfield 2.104
Ashburn 2.074
Dublin 1.838
Hong Kong 1.827
Seoul 1.655
Chandler 1.603
Hefei 1.369
Woodbridge 970
Cambridge 868
Seattle 863
Houston 797
Wilmington 758
Jacksonville 680
Beijing 627
Ann Arbor 452
Buffalo 422
Los Angeles 390
Princeton 382
Altamura 366
Lawrence 357
Florence 323
Moscow 302
Boston 296
Melbourne 285
Dallas 279
Mumbai 277
Ho Chi Minh City 266
Boardman 206
Munich 191
Kent 190
Shanghai 181
Medford 163
New York 161
The Dalles 161
São Paulo 160
Hanoi 144
San Diego 126
Clifton 104
Bremen 88
Tokyo 88
Paris 87
Helsinki 80
West Jordan 78
Jakarta 77
Redondo Beach 77
Bern 75
Bengaluru 74
Falls Church 74
Turku 73
San Jose 68
Milan 64
Abidjan 62
Norwalk 61
Dearborn 60
Rio de Janeiro 60
Rome 57
Toronto 57
Dong Ket 56
London 55
Phoenix 54
Pune 53
Izmir 51
Belo Horizonte 46
Hillsboro 46
Brussels 44
Vienna 44
Guangzhou 40
Chicago 38
Johannesburg 37
Chennai 36
Da Nang 36
Barcelona 35
Frankfurt am Main 34
Auburn Hills 32
Yubileyny 31
Brooklyn 29
Tianjin 29
Denver 27
Guayaquil 27
Haiphong 27
Cotonou 26
Andover 25
Curitiba 25
Council Bluffs 24
Montreal 24
Poplar 23
Goiânia 22
San Francisco 22
Porto Alegre 21
Quito 21
Stockholm 21
Baghdad 20
Brasília 20
Elk Grove Village 20
Atlanta 19
Biên Hòa 19
Dhaka 19
Totale 39.297
Salva come PNG Salva come JPEG
Nome #
2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds 336
MECHANISMS OF CYTOTOXICITY OF SELECTED ORGANOGOLD(III) COMPOUNDS 329
Solution Chemistry and Cytotoxic Properties of Novel Organogold(III) Compounds 328
RNA sequencing reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 327
In vitro assessment of antibody-conjugated gold nanorods for systemic injections 327
Cytotoxic activity of 3-nitropyrazolo[5,1-c][1,2,4]benzotriazine derivatives: a new series of anti-proliferative agents. 324
Proteomic Analysis of Ovarian Cancer Cell Responses to Cytotoxic Gold Compounds 316
Immunophenotypical markers, ultrastructure and chemosensitivity profile of metastatic melanoma cells. 313
Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. 313
Emerging drugs in refractory colorectal cancer 313
Effect of the SOD mimetic MnL4 on in vitro and in vivo oxaliplatin toxicity: Possible aid in chemotherapy induced neuropathy 308
Uteroglobin reverts the transformed phenotype in the endometrial adenocarcinoma cell line HEC-1A by disrupting the metabolic pathways generating platelet-activating factor 304
The complex metabolic network gearing the G1/S transition in leukemic stem cells: Hints to a rational use of antineoplastic agents. 304
Farmaci antineoplastici - Farmaci inibitori della trasduzione del segnale - Farmaci inibitori di protein chinasi 303
Natural compounds for cancer treatment and prevention 302
Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: A comparative proteomic study 296
HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment 294
Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil 293
The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways. 292
Proteomic analysis of the cytotoxic effects induced by the organogold(III) complex Aubipyc in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication 291
Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipy(c.) 288
Druggable Targets in Pancreatic Adenocarcinoma 279
High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. 277
Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer. 263
Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic Acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. 263
A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma. 255
MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin 247
Mutations of the APC gene in human sporadic colorectal cancers. 231
Selection and characterization of a human ovarian cancer cell line resistant to auranofin 224
Analysis of Gene Expression Profiles Reveals Novel Correlations With the Clinical Course of Colorectal Cancer 223
[Medical therapy of malignant melanoma] 218
Association of the HLA-G 3′UTR polymorphisms with colorectal cancer in Italy: a first insight 215
Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer 212
Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies 211
Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters 210
Editorial: multidrug resistance in cancer: pharmacological strategies from basic research to clinical issues. 207
A transcriptomic profile predicts clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 197
Analysis of Prognostic Factors for Resected Synchronous and Metachronous Liver Metastases from Colorectal Cancer. 197
N,N-bis(cyclohexanol)amine aryl esters: a new class of highly potent Pgp-dependent multidrug resistance (MDR) inhibitors 195
Biological properties of two gold(III) complexes: AuCl3(Hpm) and AuCl2(pm) 194
Treatment of locally advanced hepatocellular carcinoma by hepatic intra-artery chemotherapy: a pilot study. 192
Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. 190
Cellular pharmacology of gemcitabine. 189
Cytotoxic properties of a new organometallic platinum(II) complex and its gold(I) heterobimetallic derivatives. 186
Intracellular enhancement of intact antisense oligonucleotide steady-state levels by cationic lipids 184
RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 184
Abiraterone plus prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer: is a question of quality? 184
New structure–activity relationship studies in a series of N,N-bis(cyclohexanol)amine aryl esters as potent reversers of P-glycoprotein-mediated multidrug resistance (MDR) 183
A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy. 182
MOLECULAR CHARACTERIZATION OF ESTABLISHED HUMAN COLON CARCINOMA CELL LINES (HCT-8) MADE RESISTANT TO 5-FLUOROURACIL BY DIFFERENT SELECTION SCHEDULES 181
A novel inward-rectifying K+ current with a cell-cycle dependence governs the resting potential of mammalian neuroblastoma cells. 181
Chemistry and Biology of Two Novel Gold(I) Carbene Complexes as Prospective Anticancer Agents 181
Cytotoxicity and DNA binding properties of a chloro glycylhistidinate gold(III) complex (GHAu). 180
THE IMPACT OF GENETIC POLYMORPHISMS ON R-CHOP EFFICACY IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: AN INTERIM ANALYSIS OF A MULTICENTER PROSPECTIVE PHARMACOGENETIC STUDY 176
Exploratory Genome-Wide Association Analysis to Identify Pharmacogenetic Determinants of Response to R-CHOP in Diffuse Large B-Cell Lymphoma 172
Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors 172
Identification Of Pharmacogenomic Markers Of Clinical Efficacy In A Dose-Dense Therapy Regimen (R-Chop14) In Diffuse Large B Cell Lymphoma 171
Monitoring surface contamination for thirty antineoplastic drugs: a new proposal for surface exposure levels (SELs) 170
Update of NGS analysis of Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor) 170
LIPOSOMES LOADED WITH BERBERINE HYDROCHLORIDE: DEVELOPMENT, OPTIMISATION AND IN VITRO CITOTOXICITY 168
D13Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 168
Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study. 167
Role of Genetic Polymorphisms on Response to R-CHOP regimen in Diffuse Large B-cell Lymphoma Patients: an Interim Analysis of a Multicenter Prospective Pharmacogenetic Study 166
Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study 166
Pharmacogenetics: Implementing personalized medicine 165
Inhibitory effect of luteinising hormone-releasing hormone analogues on human endometrial cancer in vitro. 164
Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study. 164
Fluoropyrimidine-related toxicity in gastrointestinal cancer patients. Assessment of risk factors. 163
Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 162
Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: Solution behavior, reactions with model proteins, antiproliferative properties 159
Cabozantinib in advanced non-clear-cell renal cell carcinoma: is it the way clearer now? 158
Chromosomal characterization of methotrexate-resistant human T-lymphoblast leukemia cells (CCRF-CEM) with impaired polyglutamylation. 157
Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis 156
The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics 156
Cytotoxicity, DNA damage, and cell cycle perturbations induced by two representative gold(III) complexes in human leukemic cells with different cisplatin sensitivity 156
Retrospective analysis of 77 patients with ovarian cancer undergoing genetic testing for BRCA1 and BRCA2 mutations 156
Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy 156
A case report of a lung cancer patient with two uncommon EGFR mutations and a review of the literature: two sides of the same coin 156
Inflammation in Urological Malignancies: The Silent Killer 155
Added prognostic value of molecular imaging parameters over proliferation index in typical lung carcinoid: an [18F]FDG PET/CT and SSTR imaging study 153
Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression 152
Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study. 152
Differential inhibitory effects on human endometrial carcinoma cell growth of luteinizing hormone-releasing hormone analogues. 152
Germline mutations in MSH2 and ATM gene in patients with GIST (gastrointestinal stromal tumor) and second epitelial tumors 152
The clinical role of PIK3CA mutations in colorectal cancer 151
Melatonin's growth-inhibitory effect on hepatoma AH 130 in the rat. 151
Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. 150
5-methyltetrahydrofolate (mTHF) induces monocytes differentiation in HL60 cells 149
6106 POSTER Immune-boost Treatment With Gemcitabine, Oxaliplatin, Levofolinate, 5-flurouracil, Granulocyte/macrophage Colony-stimulating-factor (GM-CSF) and Aldesleukine Enhances Progression-free and Overall-survival Over FOLFOX Chemotherapy in Metastatic Colorectal Cancer Patients – Early Results From the GOLFIG-2 Phase III Trial 149
Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor) 149
Cytotoxic effects of gold(III) complexes on established human tumor cell lines sensitive and resistant to cisplatin 148
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. 148
Immune checkpoint inhibitor-induced neurologic toxicity: a case report and literature review 147
1204PGOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis 147
Role of Non-Coding RNAs in Colorectal Cancer: Focus on Long Non-Coding RNAs 146
Adverse drug reactions in oncoLogy: intEnsive monitoring program on drug toXicity of biotechnological medicatioNs anD taRget therapies in Oncologic patientS - the ALEXANDROS observational study 146
Adverse effects of macrolide antibacterials. 146
Clinical outcomes and safety of patients treated with NAb-Paclitaxel plus Gemcitabine in metastatic pancreatic cancer: the NAPA study 146
Gold(III) Complexes with Bipyridyl Ligands: Solution Chemistry, Cytotoxicity and DNA Binding Properties 145
Antimicrobial prophylaxis in orthopaedic surgery: the role of teicoplanin. 145
Totale 20.589
Salva come PNG Salva come JPEG
Categoria #
all - tutte 170.237
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 170.237
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.253 0 0 0 0 0 384 193 288 349 525 219 295
2021/20222.368 70 224 104 99 78 160 85 212 144 102 403 687
2022/20237.370 607 1.087 244 652 631 1.473 976 451 837 51 174 187
2023/20243.071 137 286 537 118 195 449 174 664 67 185 137 122
2024/202518.969 804 2.152 1.154 2.844 5.115 2.425 278 774 1.096 481 821 1.025
2025/202614.169 2.588 3.610 2.842 2.734 2.235 160 0 0 0 0 0 0
Totale 60.189